Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Hydroxyurea
Drug ID BADD_D01110
Description An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status approved
ATC Code L01XX05
DrugBank ID DB01005
KEGG ID D00341
MeSH ID D006918
PubChem ID 3657
TTD Drug ID D07CWD
NDC Product Code 0904-6939; 35369-0006; 49452-3650; 55154-7143; 61269-403; 68084-284; 70518-3615; 51927-0072; 0555-0882; 55154-3554; 69315-164; 38779-1354; 42291-321; 71770-105; 49884-724; 17337-0023; 0003-6335; 0003-6337; 60429-265; 61269-835; 70518-0916; 55512-0003; 61269-402; 71770-120; 0003-0830; 51552-0851; 62049-135; 0003-6336; 61269-404; 10135-702; 71052-323; 17337-0022
UNII X6Q56QN5QC
Synonyms Hydroxyurea | Hydroxycarbamid | Oncocarbide | Hydrea
Chemical Information
Molecular Formula CH4N2O2
CAS Registry Number 127-07-1
SMILES C(=O)(N)NO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pyoderma gangrenosum23.07.03.001; 16.32.03.005; 10.04.02.0090.000112%Not Available
Pyrexia08.05.02.0030.003750%
Radiation injury12.05.02.003--Not Available
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.0290.000168%Not Available
Rash macular23.03.13.003--Not Available
Rash maculo-papular23.03.13.004--
Rash papular23.03.13.017--Not Available
Renal cyst20.01.04.001; 16.27.01.0010.000112%Not Available
Renal disorder20.01.02.0020.000224%Not Available
Renal failure20.01.03.0050.000448%Not Available
Renal tubular disorder20.05.03.004--Not Available
Respiratory disorder22.02.07.0020.000302%Not Available
Respiratory distress22.02.01.0120.000112%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000448%
Reticulocytopenia01.07.02.004--Not Available
Retinopathy24.03.07.003; 06.10.02.0010.000112%
Rheumatoid arthritis15.01.03.001; 10.04.06.0010.000112%Not Available
Scleroderma23.03.02.005; 15.06.01.002; 10.04.07.0010.000112%Not Available
Second primary malignancy16.16.01.0140.001063%
Seizure17.12.03.001--
Sickle cell anaemia with crisis01.04.02.0010.001108%Not Available
Sinus tachycardia02.03.03.0100.000112%
Skin atrophy23.01.05.0010.000112%
Skin cancer16.03.02.002; 23.08.02.0020.000392%Not Available
Skin discolouration23.03.03.0050.000246%Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.0030.000358%Not Available
Skin hyperpigmentation23.05.01.0030.000739%
Skin irritation23.03.04.0090.000381%Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene